• +1-646-491-9876
    • +91-20-67278686

    Search

    Poliomyelitis Pipeline Review H1 2017

    Poliomyelitis Pipeline Review H1 2017

    • Report Code ID: RW0001858681
    • Category Pharmaceuticals
    • No. of Pages 69
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Poliomyelitis - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides an overview of the Poliomyelitis (Infectious Disease) pipeline landscape.

    Polio is a highly infectious disease caused by a virus. It invades the nervous system, and causes total paralysis in a matter of hours. Symptoms include fever, fatigue, headache, vomiting, stiffness in the neck and pain in the limbs. Preventive measures such as the use of vaccines are effective for polio.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Poliomyelitis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Poliomyelitis (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Poliomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Poliomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 7, 4, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II and Discovery stages comprises 1, 2 and 1 molecules, respectively.

    Poliomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Poliomyelitis (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Poliomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Poliomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Poliomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Poliomyelitis (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Poliomyelitis (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Poliomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Poliomyelitis - Overview
    Poliomyelitis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Poliomyelitis - Therapeutics Assessment
    Assessment by Target
    Assessment by Route of Administration
    Assessment by Molecule Type
    Poliomyelitis - Companies Involved in Therapeutics Development
    Beijing Minhai Biotechnology Co Ltd
    Bharat Biotech International Ltd
    Biological E Ltd
    Biological Mimetics Inc
    Boryung Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Grifols SA
    Johnson & Johnson
    Kaketsuken KK
    LG Chem, Ltd.
    Nanolek
    Panacea Biotec Ltd
    Sanofi
    Sanofi Pasteur SA
    Sentinext Therapeutics Sdn Bhd
    Shantha Biotechnics Pvt Ltd
    Taiga Biotechnologies Inc
    Takeda Pharmaceutical Company Ltd
    Poliomyelitis - Drug Profiles
    (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BK-1310 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BVN-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DTaP-IPV-HB-PRPT - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    immune globulin (human) - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ImmunoRx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IPVGVI-3000 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-2348 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KD-370 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LBVC - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LBVD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio (virus like particle, bivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio [serotype sabin 1, 3] (bivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio [strain Sabin] vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    polio vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    poliomyelitis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    poliomyelitis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    poliomyelitis vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-195 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VN-0105 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Poliomyelitis - Dormant Projects
    Poliomyelitis - Discontinued Products
    Poliomyelitis - Product Development Milestones
    Featured News & Press Releases
    Dec 10, 2015: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
    May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Poliomyelitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Poliomyelitis - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
    Poliomyelitis - Pipeline by Bharat Biotech International Ltd, H1 2017
    Poliomyelitis - Pipeline by Biological E Ltd, H1 2017
    Poliomyelitis - Pipeline by Biological Mimetics Inc, H1 2017
    Poliomyelitis - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
    Poliomyelitis - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Poliomyelitis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Poliomyelitis - Pipeline by Grifols SA, H1 2017
    Poliomyelitis - Pipeline by Johnson & Johnson, H1 2017
    Poliomyelitis - Pipeline by Kaketsuken KK, H1 2017
    Poliomyelitis - Pipeline by LG Chem, Ltd., H1 2017
    Poliomyelitis - Pipeline by Nanolek, H1 2017
    Poliomyelitis - Pipeline by Panacea Biotec Ltd, H1 2017
    Poliomyelitis - Pipeline by Sanofi, H1 2017
    Poliomyelitis - Pipeline by Sanofi Pasteur SA, H1 2017
    Poliomyelitis - Pipeline by Sentinext Therapeutics Sdn Bhd, H1 2017
    Poliomyelitis - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017
    Poliomyelitis - Pipeline by Taiga Biotechnologies Inc, H1 2017
    Poliomyelitis - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
    Poliomyelitis - Dormant Projects, H1 2017
    Poliomyelitis - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Poliomyelitis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Beijing Minhai Biotechnology Co Ltd
    Bharat Biotech International Ltd
    Biological E Ltd
    Biological Mimetics Inc
    Boryung Pharmaceutical Co Ltd
    Daiichi Sankyo Company Ltd
    GlaxoSmithKline Plc
    Grifols SA
    Johnson & Johnson
    Kaketsuken KK
    LG Chem, Ltd.
    Nanolek
    Panacea Biotec Ltd
    Sanofi
    Sanofi Pasteur SA
    Sentinext Therapeutics Sdn Bhd
    Shantha Biotechnics Pvt Ltd
    Taiga Biotechnologies Inc
    Takeda Pharmaceutical Company Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//poliomyelitis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//poliomyelitis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//poliomyelitis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments